Biocon to launch new drug in July-Sept quarter
MUMBAI (Reuters) - Biocon(BION.NS), India's top listed biotech firm, plans to launch psoriasis drug Alzumab in the country in the July-September quarter, a top company executive said on Friday.
The company expects sales of 1 billion rupees from the drug over four years, Kiran Mazumdar-Shaw, chairman, Biocon said in a conference call.
Late on Thursday, Biocon reported an 8.24 percent rise in net profit to 920 million rupees for the Oct-Dec quarter compared with a year earlier.
(Reporting by Kaustubh Kulkarni; Editing by Prateek Chatterjee)
- Tweet this
- Share this
- Digg this
Trending On Reuters
India's budget for 2015/16 highlighted the government's commitment to keeping the fiscal deficit low, ratings agency Standard and Poor's said, adding that the country's debt burden and subsidy bill could constrain its ratings. Full Article | Full Coverage